Literature DB >> 24569017

Do clinical trials of treatment of alcohol dependence adequately enroll participants with co-occurring independent mood and anxiety disorders? An analysis of data from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).

Nicolas Hoertel1, Bruno Falissard, Keith Humphreys, Philip Gorwood, Anne-Sophie Seigneurie, Frédéric Limosin.   

Abstract

BACKGROUND: In the care of alcohol-dependent patients, co-occurring independent (ie, not substance-induced) mood and anxiety disorders present a significant challenge. Clinical trials of alcohol dependence treatment could help clinicians meet this challenge, but only if they enroll such complex patients. This study examined whether such individuals are likely to be included in alcohol dependence treatment trials under typical eligibility criteria.
METHOD: Data were derived from the 2001-2002 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), a national representative sample of 43,093 adults in the United States population. Psychiatric diagnoses were made according to the DSM-IV criteria with the Alcohol Use Disorder and Associated Disabilities Interview Schedule-DSM-IV Version (AUDADIS-IV).
RESULTS: Of 1,484 alcohol-dependent participants, 39.22% (SE = 1.67) had a co-occurring independent mood or anxiety disorder; more than 60% of these individuals would be ineligible for an alcohol dependence treatment trial under typical eligibility criteria. Alcohol-dependent individuals with current major depressive episode, mania, dysthymia, panic disorder, and generalized anxiety disorder were particularly likely to be excluded from clinical trials. In a subsample of 185 individuals who had sought alcohol treatment, 52.59% (SE = 4.42) had an independent mood or anxiety disorder. Remarkably, almost all of these individuals (96.93%, SE = 1.97) would have been ineligible for clinical trials.
CONCLUSIONS: Independent mood and anxiety disorders are prevalent in the alcohol-dependent population but not in clinical trial research samples. For alcohol dependence treatment trials to adequately inform clinical practice, the enrollment of patients with co-occurring mood or anxiety disorders must be increased, through trials tailored to this population, a general relaxation of overly stringent eligibility criteria, or both. © Copyright 2014 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 24569017     DOI: 10.4088/JCP.13m08424

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  13 in total

1.  Perception of treatment need among adults with substance use disorders: Longitudinal data from a representative sample of adults in the United States.

Authors:  Scott J Moeller; Jonathan M Platt; Melody Wu; Renee D Goodwin
Journal:  Drug Alcohol Depend       Date:  2020-02-06       Impact factor: 4.492

2.  Generalizability of pharmacological and psychotherapy clinical trial results for borderline personality disorder to community samples.

Authors:  Nicolas Hoertel; Saioa López; Shuai Wang; Ana González-Pinto; Frédéric Limosin; Carlos Blanco
Journal:  Personal Disord       Date:  2015-01

Review 3.  Neurobiology of comorbid post-traumatic stress disorder and alcohol-use disorder.

Authors:  N W Gilpin; J L Weiner
Journal:  Genes Brain Behav       Date:  2016-11-18       Impact factor: 3.449

4.  Characterizing Anxiety Among Individuals Receiving Treatment for Alcohol and Substance Use Disorders.

Authors:  Lisa H Domenico; Ben Lewis; Mythili Hazarika; Sara Jo Nixon
Journal:  J Am Psychiatr Nurses Assoc       Date:  2017-11-10       Impact factor: 2.385

Review 5.  Treatment of co-occurring anxiety disorders and substance use disorders.

Authors:  R Kathryn McHugh
Journal:  Harv Rev Psychiatry       Date:  2015 Mar-Apr       Impact factor: 3.732

6.  Generalizability of Clinical Trial Results for Adolescent Major Depressive Disorder.

Authors:  Carlos Blanco; Nicolas Hoertel; Silvia Franco; Mark Olfson; Jian-Ping He; Saioa López; Ana González-Pinto; Frédéric Limosin; Kathleen R Merikangas
Journal:  Pediatrics       Date:  2017-11-02       Impact factor: 7.124

7.  Toward National Estimates of Effectiveness of Treatment for Substance Use.

Authors:  Carlos Blanco; Aimee N Campbell; Melanie M Wall; Mark Olfson; Shuai Wang; Edward V Nunes
Journal:  J Clin Psychiatry       Date:  2017-01       Impact factor: 4.384

Review 8.  Guidelines for the Reporting of Treatment Trials for Alcohol Use Disorders.

Authors:  Katie Witkiewitz; John W Finney; Alex H S Harris; Daniel R Kivlahan; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2015-08-11       Impact factor: 3.455

Review 9.  Recommendations for the Design and Analysis of Treatment Trials for Alcohol Use Disorders.

Authors:  Katie Witkiewitz; John W Finney; Alex H S Harris; Daniel R Kivlahan; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2015-08-06       Impact factor: 3.455

Review 10.  The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) Waves 1 and 2: review and summary of findings.

Authors:  Deborah S Hasin; Bridget F Grant
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2015-07-26       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.